Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.

Tytuł:
EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
Autorzy:
Doubková M; Department of Phthisiology Pulmonary Diseases and Tuberculosis, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic.
Švancara J; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Svoboda M; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Šterclová M; Department of Respiratory Medicine, First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.
Bartoš V; Department of Pneumology, Faculty of Medicine and Charles University, Hradec Králové, Czech Republic.
Plačková M; Department of Pneumology, University Hospital in Ostrava, Faculty of Medicine, Pilsen, Charles University, Czech Republic.
Lacina L; Department of Pneumology and Thoracic Surgery, Hospital Na Bulovce, Prague, Czech Republic.
Žurková M; Department of Respiratory Medicine, Faculty of Medicine and Palacky University Hospital Olomouc, Czech Republic.
Binková I; Department of Phthisiology Pulmonary Diseases and Tuberculosis, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic.
Bittenglová R; Department of Respiratory Diseases, Faculty of Medicine and Charles University Hospital Pilsen, Czech Republic.
Lošťáková V; Department of Respiratory Medicine, Faculty of Medicine and Palacky University Hospital Olomouc, Czech Republic.
Merta Z; Department of Phthisiology Pulmonary Diseases and Tuberculosis, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic.
Šišková L; Department of Respiratory Diseases, Tomáš Baťa Regional Hospital, Zlín, Czech Republic.
Tyl R; Department of Respiratory Diseases, Nový Jičín Hospital, Czech Republic.
Lisá P; Department of Pneumology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Šuldová H; Pulmonary Department, České Budějovice Hospital, Czech Republic.
Petřík F; Department of Pneumology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Pšikalová J; PneumoAllergolog Department, Kromeříž Hospital, Czech Republic.
Řihák V; Department of Respiratory Diseases, Tomáš Baťa Regional Hospital, Zlín, Czech Republic.
Snížek T; Department of Respiratory Diseases, Jihlava Hospital, Czech Republic.
Reiterer P; Department of Pulmonary Diseases and Tuberculosis, Masaryk Hospital, Ústí nad Labem, Czech Republic.
Homolka J; First Department of Tuberculosis and Respiratory Diseases, General Hospital in Prague and The First Medical Faculty of Charles University, Czech Republic.
Musilová P; Department of Respiratory Diseases, Jihlava Hospital, Czech Republic.
Lněnička J; Department of Pulmonary Diseases and Tuberculosis, Masaryk Hospital, Ústí nad Labem, Czech Republic.
Palúch P; Department of Respiratory Medicine, First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.
Hrdina R; Department of Respiratory Diseases, Znojmo Hospital, Czech Republic.
Králová R; Department of Respiratory Diseases, Pardubice Hospital, Czech Republic.
Hortvíková H; Department of Pneumology, University Hospital in Ostrava, Faculty of Medicine, Pilsen, Charles University, Czech Republic.
Strenková J; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Vašáková M; Department of Respiratory Medicine, First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.
Źródło:
The clinical respiratory journal [Clin Respir J] 2018 Apr; Vol. 12 (4), pp. 1526-1535. Date of Electronic Publication: 2017 Sep 26.
Typ publikacji:
Journal Article; Meta-Analysis
Język:
English
Imprint Name(s):
Original Publication: Oxford : Blackwell Publishing
MeSH Terms:
Registries*
Idiopathic Pulmonary Fibrosis/*diagnosis
Lung/*physiopathology
Tomography, X-Ray Computed/*methods
Vital Capacity/*physiology
Aged ; Aged, 80 and over ; Czech Republic/epidemiology ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Idiopathic Pulmonary Fibrosis/epidemiology ; Idiopathic Pulmonary Fibrosis/physiopathology ; Incidence ; Lung/diagnostic imaging ; Lung Volume Measurements ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate/trends
Contributed Indexing:
Keywords: IPF registry; idiopathic pulmonary fibrosis; prognostic factors; pulmonary functions
Entry Date(s):
Date Created: 20170902 Date Completed: 20181003 Latest Revision: 20181004
Update Code:
20240105
DOI:
10.1111/crj.12700
PMID:
28862397
Czasopismo naukowe
Introduction: Prognostic factors of idiopathic pulmonary fibrosis (IPF) currently recognized include changes in vital capacity and radiologic findings. However, most of the prognostic studies in IPF are based on clinical studies with preselected IPF populations. Therefore, we decided to analyze the factors influencing IPF prognosis based on the real-practice data from our IPF registry.
Methods: Data of 514 subjects consecutively entered since 2012 into Czech EMPIRE IPF registry were analyzed.
Results: Median age of our patient cohort was 67 years (50-82). Median overall survival (OS) of the cohort was 63.1 months. The clinical course of IPF according to FVC (forced vital capacity) changes was stabilized in 32.8% of patients (29.7% according to DL CO [diffuse lung capacity] changes), slowly progressive in 39.5% (45%), rapidly progressive in 23.5% (20.7%); and 1.7% patients had at least one acute exacerbation during follow-up. Deterioration in FVC of ≥10% at month 12 and in DL CO of ≥15% at months 12, 18, and 24 influenced the OS significantly. The fast progressors defined by the DL CO decline rate had higher risk of death compared to those defined by the FVC change over time. In multivariate analysis, age ≥70 years, interstitial HRCT scores ≥3, and change in DL CO of ≥15% at month 12 were confirmed as factors negatively influencing OS.
Conclusions: DL CO changes over time were shown as a better predictor of mortality compared with FVC changes in our study. In our opinion it is necessary to implement the DL CO analysis into clinical trials and routine practice.
(© 2017 John Wiley & Sons Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies